Abiraterone acetate (abiraterone for short, trade name: Zytiga) has been approved in Germany since December 2012 for men with metastatic prostate cancer that is not responsive to hormone blockade, who only have mild symptoms ...
Jul 2, 2013
0
1
A new drug called pyrvinium pamoate inhibits aggressive forms of prostate cancer that are resistant to standard drugs, according to a study conducted in an animal model. The results will be presented Monday at The Endocrine ...
Jun 17, 2013
0
0
(Medical Xpress)—For the past 70 years, androgen deprivation therapy (ADT) has been the standard treatment for men diagnosed with late-stage prostate cancer.
Jun 14, 2013
0
0
Researchers at the University of Adelaide are spearheading a new direction in prostate cancer research, with the potential for new treatments of the disease.
Jun 3, 2013
0
0
Researchers have identified a sub-group of cells that could contribute to prostate cancer recurrence, opening up new ways to treat the disease, which claims more than 3000 lives a year in Australia.
May 29, 2013
0
0
Dr. Jung-Mo Ahn, associate professor of chemistry at The University of Texas at Dallas, has designed and synthesized a novel small molecule that might become a large weapon in the fight against prostate cancer.
May 28, 2013
0
5
A new study on prostate cancer describes a novel class of drugs developed by UT Southwestern Medical Center researchers that interrupts critical signaling needed for prostate cancer cells to grow.
May 28, 2013
0
0
There is a link between use of anabolic-androgenic steroids and reduced mental health later in life. This is the main conclusion of a new study on elite male strength athletes that researchers from the University of Gothenburg ...
May 20, 2013
1
1
Androgen deprivation therapy is a common and effective treatment for advanced prostate cancer. However, among other side-effects, it can cause significant bone thinning in men on long-term treatment. A new study¹ by Vahakn ...
May 14, 2013
1
0
Estrogen and progesterone receptors, and the gene HER2 – these are the big three markers and/or targets in breast cancer. Evidence presented at the AACR Annual Meeting 2013 adds a fourth: androgen receptors.
Apr 10, 2013
0
0
